
Autistic Disorder- Pipeline Insight, 2025
Description
DelveInsight’s, “Autistic Disorder - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Autistic Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Autistic Disorder: Overview
Autism Spectrum Disorder (ASD) encompasses a range of neurodevelopmental disorders characterized by repetitive behaviors, restricted interests, and challenges in social interactions. It is a complex condition that manifests in early childhood and significantly impacts daily functioning. Children with ASD often experience distress when changes occur in their environment due to limited adaptability. In addition to behavioral symptoms, ASD is frequently associated with co-occurring issues such as language impairments, intellectual disabilities, and epilepsy. Childhood Disintegrative Disorder (CDD), also known as disintegrative psychosis or Heller syndrome, is a rare and severe form of ASD, marked by a significant regression in social, language, and motor skills after a period of normal development, typically after the age of three. Though the exact cause of CDD is unknown, it often presents with rapid skill loss that may lead to confusion or distress for the affected child. This disorder can be devastating for both the individual and their family, as it disrupts previously acquired developmental milestones.
The exact cause of ASD remains unknown, and its onset is often insidious, with no clearly defined trigger. While children with ASD have a higher risk of developing epilepsy, no direct causal relationship has been established. Childhood Disintegrative Disorder (CDD), a subtype of ASD, has been associated with several diseases, especially when it manifests with a late onset. These include subacute sclerosing panencephalitis, a chronic brain infection caused by a form of the measles virus leading to brain inflammation and nerve cell death; tuberous sclerosis, a genetic disorder that causes benign tumors in the brain and other organs; leukodystrophy, a condition involving the degeneration of white matter in the brain due to improper myelin sheath development; and lipid storage diseases, which involve the toxic accumulation of fats in the brain and nervous system.
The pathophysiology of Autism Spectrum Disorder (ASD) remains unclear, though various subtypes of the disorder may have distinct underlying mechanisms. For example, Childhood Disintegrative Disorder (CDD) occurs in children who initially achieve normal developmental milestones, but experience a rapid regression of skills, typically around the fourth year of life, though onset can vary. This sudden loss of skills has led some to consider CDD a form of childhood dementia, with the possibility that amyloid deposition in the brain may play a role in the disease’s progression. However, this hypothesis remains unproven and requires further research to establish a definitive link.
The approach for treatment is behavior-based and highly structured, aiming to help children re-learn language, self-care, and social skills. Family counseling is essential, ensuring that parents are equipped to support their child’s treatment at home. Various therapies, including speech, occupational, social skills development, and sensory integration, are tailored to each child's needs. As children with CDD experience profound skill regression, they often require long-term care. Treatment includes behavior therapy, environmental therapy, and medications. Behavior therapy often uses Applied Behavioral Analysis (ABA) with a reward system to reinforce positive behaviors and reduce problematic ones. Environmental therapy enhances sensory experiences to manage sensory processing difficulties. Medications are prescribed to manage symptoms, such as antipsychotics for repetitive behaviors and aggression, while SSRIs, stimulants, and other antipsychotics help with behavioral control. If seizures occur, anticonvulsants are used. However, there is a risk of neuroleptic malignant syndrome with neuroleptic medications, and no direct cure for CDD exists.
""Autistic Disorder - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autistic Disorder pipeline landscape is provided which includes the disease overview and Autistic Disorder treatment guidelines. The assessment part of the report embraces, in depth Autistic Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Autistic Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Autistic Disorder Emerging Drugs
Further product details are provided in the report……..
Autistic Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Autistic Disorder drugs segregated based on following parameters that define the scope of the report, such as:
Autistic Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Autistic Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Autistic Disorder drugs.
Autistic Disorder Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Autistic Disorder: Overview
Autism Spectrum Disorder (ASD) encompasses a range of neurodevelopmental disorders characterized by repetitive behaviors, restricted interests, and challenges in social interactions. It is a complex condition that manifests in early childhood and significantly impacts daily functioning. Children with ASD often experience distress when changes occur in their environment due to limited adaptability. In addition to behavioral symptoms, ASD is frequently associated with co-occurring issues such as language impairments, intellectual disabilities, and epilepsy. Childhood Disintegrative Disorder (CDD), also known as disintegrative psychosis or Heller syndrome, is a rare and severe form of ASD, marked by a significant regression in social, language, and motor skills after a period of normal development, typically after the age of three. Though the exact cause of CDD is unknown, it often presents with rapid skill loss that may lead to confusion or distress for the affected child. This disorder can be devastating for both the individual and their family, as it disrupts previously acquired developmental milestones.
The exact cause of ASD remains unknown, and its onset is often insidious, with no clearly defined trigger. While children with ASD have a higher risk of developing epilepsy, no direct causal relationship has been established. Childhood Disintegrative Disorder (CDD), a subtype of ASD, has been associated with several diseases, especially when it manifests with a late onset. These include subacute sclerosing panencephalitis, a chronic brain infection caused by a form of the measles virus leading to brain inflammation and nerve cell death; tuberous sclerosis, a genetic disorder that causes benign tumors in the brain and other organs; leukodystrophy, a condition involving the degeneration of white matter in the brain due to improper myelin sheath development; and lipid storage diseases, which involve the toxic accumulation of fats in the brain and nervous system.
The pathophysiology of Autism Spectrum Disorder (ASD) remains unclear, though various subtypes of the disorder may have distinct underlying mechanisms. For example, Childhood Disintegrative Disorder (CDD) occurs in children who initially achieve normal developmental milestones, but experience a rapid regression of skills, typically around the fourth year of life, though onset can vary. This sudden loss of skills has led some to consider CDD a form of childhood dementia, with the possibility that amyloid deposition in the brain may play a role in the disease’s progression. However, this hypothesis remains unproven and requires further research to establish a definitive link.
The approach for treatment is behavior-based and highly structured, aiming to help children re-learn language, self-care, and social skills. Family counseling is essential, ensuring that parents are equipped to support their child’s treatment at home. Various therapies, including speech, occupational, social skills development, and sensory integration, are tailored to each child's needs. As children with CDD experience profound skill regression, they often require long-term care. Treatment includes behavior therapy, environmental therapy, and medications. Behavior therapy often uses Applied Behavioral Analysis (ABA) with a reward system to reinforce positive behaviors and reduce problematic ones. Environmental therapy enhances sensory experiences to manage sensory processing difficulties. Medications are prescribed to manage symptoms, such as antipsychotics for repetitive behaviors and aggression, while SSRIs, stimulants, and other antipsychotics help with behavioral control. If seizures occur, anticonvulsants are used. However, there is a risk of neuroleptic malignant syndrome with neuroleptic medications, and no direct cure for CDD exists.
""Autistic Disorder - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autistic Disorder pipeline landscape is provided which includes the disease overview and Autistic Disorder treatment guidelines. The assessment part of the report embraces, in depth Autistic Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Autistic Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Autistic Disorder.
This segment of the Autistic Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Autistic Disorder Emerging Drugs
- AST-001: Astrogen, Inc.
- L1-79: Yamo Pharmaceuticals LLC
- AB-2004: Axial Therapeutics, Inc.
Further product details are provided in the report……..
Autistic Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Autistic Disorder drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Autistic Disorder
- There are approx. 18+ key companies which are developing the therapies for Autistic Disorder. The companies which have their Autistic Disorder drug candidates in the most advanced stage, i.e. Phase III include, Astrogen, Inc.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Autistic Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Autistic Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Autistic Disorder drugs.
Autistic Disorder Report Insights
- Autistic Disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Autistic Disorder drugs?
- How many Autistic Disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Autistic Disorder?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Autistic Disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Autistic Disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
- Astrogen, Inc.
- Yamo Pharmaceuticals LLC
- Axial Therapeutics, Inc.
- NeuroNOS
- Shanghai Auzone Biological Technology Co., Ltd.
- Vanda Pharmaceuticals
- Paxmedica
- Stalicla SA
- ACADIA Pharmaceuticals Inc.
- MapLight Therapeutics
- Intra-Cellular Therapies, Inc.
- Aardvark Therapeutics, Inc.
- Astrogen, Inc.
- IAMA Therapeutics S.r.l.
- GEXVal
- AST-001
- L1-79
- AB-2004
- BA102
- TTYP01
- Tasimelteon
- Suramin Sodium
- Pimavanserin
- ML-004
- Lumateperone
- ARD-501
- Cannabidivarin
- AST-001
- AB-2004
- GXV 001
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Autistic Disorder: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Autistic Disorder– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- AST-001: Astrogen, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- L1-79: Yamo Pharmaceuticals LLC
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Autistic Disorder Key Companies
- Autistic Disorder Key Products
- Autistic Disorder- Unmet Needs
- Autistic Disorder- Market Drivers and Barriers
- Autistic Disorder- Future Perspectives and Conclusion
- Autistic Disorder Analyst Views
- Autistic Disorder Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.